A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

The age groups tagged for this paper are children, teenagers and adults, women only.

Nineteen untreated girls with TS, mean (SD) baseline pretreatment age 13.3 (1.7) (range 11.0-17.6) year.

Before and during GH treatment, measurements of volumetric BMD were performed using phalangeal radiographic absorptiometry.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

In addition, the BMD measurements were repeated three years after discontinuation of GH treatment.

BMD results were adjusted for bone age and sex, and expressed as SD-scores (SDS) using reference values of healthy Dutch girls.

What Was Measured

Topics PubMed links to this paper include Age Determination by Skeleton, Body Height, Bone Density, Bone and Bones, Ethinyl Estradiol, Fingers and Hand.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.